VRTX * Stock Overview A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Vertex Pharmaceuticals Incorporated Competitors Price History & Performance
Summary of share price highs, lows and changes for Vertex Pharmaceuticals Historical stock prices Current Share Price US$9,483.40 52 Week High US$10,477.52 52 Week Low US$6,530.25 Beta 0.41 1 Month Change 8.75% 3 Month Change 2.34% 1 Year Change 33.68% 3 Year Change 101.69% 5 Year Change 116.15% Change since IPO 836.18%
Recent News & Updates
Vertex Pharmaceuticals Incorporated Executive Changes Feb 11
Full year 2024 earnings released: US$2.08 loss per share (vs US$14.05 profit in FY 2023) Feb 11
Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Full Year 2025 Feb 11
Vertex Pharmaceuticals Incorporated Announces FDA Approval of Journavx (Suzetrigine), A First-In-Class Treatment for Adults with Moderate-To-Severe Acute Pain Jan 31
Vertex Pharmaceuticals Incorporated to Report Q4, 2024 Results on Feb 10, 2025 Jan 27
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21 See more updates
Vertex Pharmaceuticals Incorporated Executive Changes Feb 11
Full year 2024 earnings released: US$2.08 loss per share (vs US$14.05 profit in FY 2023) Feb 11
Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Full Year 2025 Feb 11
Vertex Pharmaceuticals Incorporated Announces FDA Approval of Journavx (Suzetrigine), A First-In-Class Treatment for Adults with Moderate-To-Severe Acute Pain Jan 31
Vertex Pharmaceuticals Incorporated to Report Q4, 2024 Results on Feb 10, 2025 Jan 27
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023) Nov 06
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11
Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023) Aug 02
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Aug 02
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain Jul 31 Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations Jul 16
Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Jun 22
Investor sentiment improves as stock rises 19% Jun 07
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders. May 21
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director May 16
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024 May 08
First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023) May 07
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older Apr 27
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion. Apr 11
Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024 Apr 10
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024 Apr 05 Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older Feb 23
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Feb 13
Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis Feb 07
Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022) Feb 06
Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024 Feb 06
Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain Jan 30
Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024 Jan 18
Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 17
Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Jan 10
Investor sentiment improves as stock rises 16% Dec 19
Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Dec 16
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy Dec 14 CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States
Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director Dec 06
Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older Nov 30
Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Nov 24
Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY Nov 17
Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022) Nov 09
Now 21% undervalued Oct 31
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation Oct 18
Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors Oct 06
Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5 Sep 16
Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Aug 30
Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine Aug 04
Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022) Aug 03
Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old Jul 06
Insufficient new directors Jul 01
Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions Jun 24
Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Jun 10
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 09
First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022) May 03
Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021) Feb 08
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares. Feb 08
Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Now 21% undervalued after recent price drop Jan 03
Now 21% undervalued Dec 19
Now 20% undervalued Nov 29
Now 22% undervalued Nov 04
Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference Nov 04
Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021) Oct 28
Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022 Oct 28
Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency Oct 12
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 Sep 28
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 10
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 09
Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months Sep 03
Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021) Aug 05
Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022 Aug 05
Vertex Advances VX-548 in Acute and Neuropathic Pain Jul 23
Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 19
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 13
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 12
Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Jul 06
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Jun 11
Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Jun 09
Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial Jun 01
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 25
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 24
Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director May 19
First quarter 2022 earnings released: EPS: US$2.99 (vs US$2.52 in 1Q 2021) May 06
Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022 May 06
Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022 Apr 22
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation Apr 21
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022 Apr 08
Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain Apr 01
Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA Mar 28 Shareholder Returns VRTX * MX Biotechs MX Market 7D 0% 0% 0% 1Y 33.7% 0% 0%
See full shareholder returns
Return vs Industry: VRTX * exceeded the MX Biotechs industry which returned 1.6% over the past year.
Return vs Market: VRTX * exceeded the MX Market which returned -7.9% over the past year.
Price Volatility Is VRTX *'s price volatile compared to industry and market? VRTX * volatility VRTX * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: VRTX *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine VRTX *'s volatility change over the past year.
About the Company Founded Employees CEO Website 1989 6,100 Reshma Kewalramani www.vrtx.com
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
Show more Vertex Pharmaceuticals Incorporated Fundamentals Summary How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap? VRTX * fundamental statistics Market cap Mex$2.47t Earnings (TTM ) -Mex$10.91b Revenue (TTM ) Mex$224.45b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VRTX * income statement (TTM ) Revenue US$11.02b Cost of Revenue US$1.53b Gross Profit US$9.49b Other Expenses US$10.03b Earnings -US$535.60m
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) -2.09 Gross Margin 86.11% Net Profit Margin -4.86% Debt/Equity Ratio 0%
How did VRTX * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/20 05:49 End of Day Share Price 2025/02/11 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Vertex Pharmaceuticals Incorporated is covered by 66 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
Show 63 more analysts 
